Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HSD17B3 | P37058 | 7/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.45 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1611987 | 0.89 | THRA (0.46) | THRATHRBHSD17B3HCAR3ALDH1A1 | |
| SCHEMBL1612238 | 0.82 | THRA (0.51) | THRATHRBHSD17B3PDK1HCAR3 | |
| SCHEMBL16016907 | 0.81 | THRA (0.48) | THRATHRBHSD17B3PDK1HCAR3 | |
| SCHEMBL11765445 | 0.78 | LMNA (0.57) | THRATHRBHSD17B3HCAR3ALDH1A1 | |
| SCHEMBL11444533 | 0.78 | TSHR (0.60) | THRATHRBHSD17B3HCAR3ALDH1A1 | |
| SCHEMBL28029786 | 0.77 | HCAR3 (0.53) | THRATHRBHSD17B3HCAR3GAA | |
| SCHEMBL17576549 | 0.77 | CASP6 (0.64) | PDK1HCAR3LMNA | |
| SCHEMBL28662445 | 0.76 | PDK1 (0.56) | PDK1HCAR3ALDH1A1GAAHPGD | |
| SCHEMBL9439906 | 0.74 | ALDH1A1 (0.63) | HSD17B3ALDH1A1HTR7LMNA | |
| SCHEMBL19411243 | 0.74 | HCAR3 (0.55) | THRATHRBHSD17B3HCAR3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110087013-A1 | Friedel-Crafts acylation for the synthesis of aryl- and heteroaryl-(3-ethyl-4-nitrophenyl)-methanones | ROCHE NIMBLEGEN, INC. | 2011-04-14 | — | — | US | claimed |
| US-20110087013-A1 | Friedel-Crafts acylation for the synthesis of aryl- and heteroaryl-(3-ethyl-4-nitrophenyl)-methanones | ROCHE NIMBLEGEN, INC. | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110087013-A1 | Friedel-Crafts acylation for the synthesis of aryl- and heteroaryl-(3-ethyl-4-nitrophenyl)-methanones | CYP2B6, HNF4A, AHR | THRA 1841/4885THRB 2017/4885HSD17B3 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.